Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Author(s)Natalie Hollon, PharmD, Viet Dang, PharmD Candidate, Grace Eramo, PhD Candidate

Fact checked by: Luke Halpern, Associate Editor

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

A group of experts will present an encore abstract titled "Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using Real-World Data" at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20. The abstract was originally shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.